首页> 外文期刊>Nanomedicine >A solid self-nanoemulsifying system of the BCS class IIb drug dabigatran etexilate to improve oral bioavailability
【24h】

A solid self-nanoemulsifying system of the BCS class IIb drug dabigatran etexilate to improve oral bioavailability

机译:BCS IIb类药物达比加群酯的固体自纳米乳化系统,可改善口服生物利用度

获取原文
获取原文并翻译 | 示例
           

摘要

Aim: To develop dabigatran etexilate (DE)-loaded self-nanoemulsifying drug delivery systems (SNEDDS) for the prevention of stroke and thromboembolism. Materials & methods: SNEDDS were optimized by ternary phase diagrams and then further solidified into dispersible tablets. In vitro dissolution was analyzed by a phase distribution study. In situ absorption and in vivo pharmacokinetic studies were tested in male Sprague-Dawley rats. Results: The phase distribution study showed that more than 60% of DE was retained in the oil phase. Dissolution rate was dramatically enhanced without significant precipitation (<30%) in simulated intestinal fluid. Optimized SNEDDS had 531.80% relative bioavailability compared with Pradaxa (R) capsules (a commercial DE product). Conclusion: The developed SNEDDS are promising materials for improving the dissolution and oral bioavailability of BCS class IIb drugs.
机译:目的:开发载有达比加群酯(DE)的自纳米乳化药物递送系统(SNEDDS),以预防中风和血栓栓塞。材料和方法:SNEDDS通过三元相图进行了优化,然后进一步固化为可分散的片剂。通过相分布研究分析了体外溶出度。在雄性Sprague-Dawley大鼠中测试了原位吸收和体内药代动力学研究。结果:相分布研究表明,超过60%的DE保留在油相中。在模拟的肠液中,溶出率得到显着提高,而没有明显的沉淀(<30%)。与Pradaxa(R)胶囊(一种商用DE产品)相比,优化的SNEDDS的相对生物利用度为531.80%。结论:已开发的SNEDDS是改善BCS IIb类药物的溶出度和口服生物利用度的有前途的材料。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号